Legal
Glenmark Settles State Price-Fixing Claims for $29.6 Million
Glenmark Pharmaceuticals agreed to pay $29.6 million to settle price-fixing allegations brought by multiple states. The settlement resolves a multi-year investigation into alleged anti-competitive conduct involving drug pricing. The agreement covers claims from dozens of states that alleged Glenmark engaged in collusion to fix prices on generic pharmaceuticals. This settlement follows a pattern of similar enforcement actions against generic drug manufacturers over the past several years.
Why it mattersGeneric drug price-fixing settlements can affect Medicaid managed care organizations through pharmacy benefit costs, rebate calculations, and best price determinations under the Medicaid Drug Rebate Program.